Case report: Combinations of immune checkpoint inhibitor, chemotherapy, and hyperthermia therapy avoid lymphatic recurrence in cholangiocarcinoma

被引:0
|
作者
Chang, Heng-Jui [1 ]
Ke, Chiao-Hsu [2 ]
Wang, Yu-Shan [3 ,4 ]
机构
[1] Wesing Surg Hosp, Dept Radiat Oncol, Kaohsiung, Taiwan
[2] Natl Taipei Univ Technol, Inst Chem Engn, Dept Chem Engn & Biotechnol, Taipei, Taiwan
[3] Natl Taiwan Univ, Sch Vet Med, Dept Vet Med, Taipei, Taiwan
[4] Uni Pharm Co Ltd, Taipei, Taiwan
来源
FRONTIERS IN ONCOLOGY | 2024年 / 14卷
关键词
immune checkpoint inhibitor; hyperthermia; modulated electro-hyperthermia; cholangiocarcinoma; immunotherapy;
D O I
10.3389/fonc.2024.1421340
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Cholangiocarcinoma is a malignancy known for its aggressiveness and limited treatment options. The malignant tumor behaviors include intrahepatic recurrence, regional lymph node (LN) metastasis, peritoneal carcinomatosis, and lung metastasis. Herein, we reported a case of lymphatic recurrence in an intrahepatic cholangiocarcinoma patient after surgery, adjuvant concurrent chemoradiotherapy (CCRT), who experienced a remarkable response to a combination therapy. However, the patient failed to undergo radiotherapy or other invasive local therapy and therefore received Opdivo (nivolumab) in combination with chemotherapy (FOLFOX) and modulated electro-hyperthermia. Notably, after these medical interventions, this patient had a complete response (CR) to treatments, in which no lymph node metastasis occurred, and a significantly decreased tumor marker, CA 19-9, level was found. This case highlights the potential of multiple anti-tumor therapies, including immune checkpoint inhibitors, chemotherapy, and hyperthermia, in managing challenging cholangiocarcinoma cases.
引用
收藏
页数:7
相关论文
共 50 条
  • [1] Case Report: Persistent response to combination therapy of pemigatinib, chemotherapy, and immune checkpoint inhibitor in a patient with advanced intrahepatic cholangiocarcinoma
    Zhang, Zhuochao
    Wang, Gaofei
    Du, Lei
    Zhao, Jie
    Pan, Lichao
    Zhang, Gong
    Wang, Fei
    Liu, Rong
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [2] Immune checkpoint inhibitor therapy in biliary tract cancer (cholangiocarcinoma)
    Jakubowski, Christopher D.
    Azad, Nilofer S.
    CHINESE CLINICAL ONCOLOGY, 2020, 9 (01)
  • [3] Case report: hypertrophic osteoarthropathy improves with immune checkpoint inhibitor therapy
    Moon, David
    Chu, Quincy
    Ye, Carrie
    JOURNAL OF CHEMOTHERAPY, 2024,
  • [4] Combination therapy with local hyperthermia and immune checkpoint inhibitor for osteosarcoma in mice
    Izubuchi, Yuya
    Tanaka, Takaaki
    Matsumine, Akihiko
    CANCER SCIENCE, 2021, 112 : 851 - 851
  • [5] Myocarditis associated with immune checkpoint inhibitor therapy: a case report of three patients
    Kianoush Ansari-Gilani
    Sree Harsha Tirumani
    Daniel A. Smith
    Ariel Nelson
    Asrar Alahmadi
    Christopher J. Hoimes
    Nikhil H. Ramaiya
    Emergency Radiology, 2020, 27 : 455 - 460
  • [6] Myocarditis associated with immune checkpoint inhibitor therapy: a case report of three patients
    Ansari-Gilani, Kianoush
    Tirumani, Sree Harsha
    Smith, Daniel A.
    Nelson, Ariel
    Alahmadi, Asrar
    Hoimes, Christopher J.
    Ramaiya, Nikhil H.
    EMERGENCY RADIOLOGY, 2020, 27 (04) : 455 - 460
  • [7] New DKA in a geriatric patient on immune checkpoint inhibitor therapy: a case report
    Anton Nikouline
    Mike Brzozowski
    Canadian Journal of Emergency Medicine, 2021, 23 : 712 - 714
  • [8] Rilonacept for Refractory Pericarditis Following Immune Checkpoint Inhibitor Therapy: A Case Report
    Hamandi, Mohanad
    Gooch, Janelle
    Levenson, Joshua E.
    CIRCULATION, 2023, 148
  • [9] New DKA in a geriatric patient on immune checkpoint inhibitor therapy: a case report
    Nikouline, Anton
    Brzozowski, Mike
    CANADIAN JOURNAL OF EMERGENCY MEDICINE, 2021, 23 (05) : 712 - 714
  • [10] Second primary tumor after immune checkpoint inhibitor therapy: A case report
    Miao, Kang
    Yu, Shuangni
    Ni, Jun
    Zhang, Xiaotong
    Zhang, Li
    THORACIC CANCER, 2022, 13 (07) : 1076 - 1078